Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome.

OBJECTIVES We sought to determine both the procedural performance and safety of percutaneous implantation of the second (21-French [F])- and third (18-F)-generation CoreValve aortic valve prosthesis (CoreValve Inc., Irvine, California). BACKGROUND Percutaneous aortic valve replacement represents an emerging alternative therapy for high-risk and inoperable patients with severe symptomatic aortic valve stenosis. METHODS Patients with: 1) symptomatic, severe aortic valve stenosis (area <1 cm2); 2) age > or =80 years with a logistic EuroSCORE > or =20% (21-F group) or age > or =75 years with a logistic EuroSCORE > or =15% (18-F group); or 3) age > or =65 years plus additional prespecified risk factors were included. Introduction of the 18-F device enabled the transition from a multidisciplinary approach involving general anesthesia, surgical cut-down, and cardiopulmonary bypass to a truly percutaneous approach under local anesthesia without hemodynamic support. RESULTS A total of 86 patients (21-F, n = 50; 18-F, n = 36) with a mean valve area of 0.66 +/- 0.19 cm2 (21-F) and 0.54 +/- 0.15 cm2 (18-F), a mean age of 81.3 +/- 5.2 years (21-F) and 83.4 +/- 6.7 years (18-F), and a mean logistic EuroSCORE of 23.4 +/- 13.5% (21-F) and 19.1 +/- 11.1% (18-F) were recruited. Acute device success was 88%. Successful device implantation resulted in a marked reduction of aortic transvalvular gradients (mean pre 43.7 mm Hg vs. post 9.0 mm Hg, p < 0.001) with aortic regurgitation grade remaining unchanged. Acute procedural success rate was 74% (21-F: 78%; 18-F: 69%). Procedural mortality was 6%. Overall 30-day mortality rate was 12%; the combined rate of death, stroke, and myocardial infarction was 22%. CONCLUSIONS Treatment of severe aortic valve stenosis in high-risk patients with percutaneous implantation of the CoreValve prosthesis is feasible and associated with a lower mortality rate than predicted by risk algorithms.

[1]  Thomas Felderhoff,et al.  First report on a human percutaneous transluminal implantation of a self‐expanding valve prosthesis for interventional treatment of aortic valve stenosis , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  Assaf Bash,et al.  Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description , 2002, Circulation.

[3]  F. Larrazet,et al.  Evolution of the postoperative pericardial effusion after day 15: the problem of the late tamponade. , 2004, Chest.

[4]  A. Cheung,et al.  Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  B. Astor,et al.  Mortality after aortic valve replacement: results from a nationally representative database. , 2000, The Annals of thoracic surgery.

[6]  Thomas Felderhoff,et al.  Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease: The Siegburg First-in-Man Study , 2006 .

[7]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[8]  M. Mittlböck,et al.  EuroSCORE predicts mid-term outcome after combined valve and coronary bypass surgery. , 2004, The Journal of heart valve disease.

[9]  A. Cribier,et al.  Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. , 2006, Journal of the American College of Cardiology.

[10]  Younes Boudjemline,et al.  Steps Toward Percutaneous Aortic Valve Replacement , 2002, Circulation.

[11]  Thomas Felderhoff,et al.  Percutaneous Implantation of the CoreValve Self-Expanding Valve Prosthesis in High-Risk Patients With Aortic Valve Disease: The Siegburg First-in-Man Study , 2006, Circulation.

[12]  J Kachaner,et al.  Transcatheter implantation of a bovine valve in pulmonary position: a lamb study. , 2000, Circulation.

[13]  R. Bergström,et al.  Long-term follow-up of morbidity and mortality after aortic valve replacement with a mechanical valve prosthesis. , 2000, European heart journal.

[14]  J M Hasenkam,et al.  Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. , 1992, European heart journal.

[15]  Philippe Ravaud,et al.  Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? , 2005, European heart journal.

[16]  Christopher E. Buller,et al.  Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery , 2006, Circulation.

[17]  Anson Cheung,et al.  Transapical Transcatheter Aortic Valve Implantation in Humans: Initial Clinical Experience , 2006, Circulation.

[18]  A. Galloway,et al.  Aortic valve replacement in patients with impaired ventricular function. , 2003, The Annals of thoracic surgery.

[19]  K. Anstrom,et al.  Outcomes of cardiac surgery in patients > or = 80 years: results from the National Cardiovascular Network. , 2000, Journal of the American College of Cardiology.